Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elacytarabine vs Investigator's Choice in Late Stage AML
NCT01147939Phase 3Completed
- Sponsor
- Clavis Pharma
- Start
- Jun 2010
- Primary completion
- Feb 2013
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of elacytarabine in acute myeloid leukemia (AML) (2 arms), sponsored by Clavis Pharma. Primary endpoint: Overall Survival. Started Jun 2010; status: completed.
02
Drugs
elacytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01147939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01147939.